Taking on board COVID-19 vaccine approval euphoria plus growth prospects
30/12/20 -"With UK’s emergency use approval for Astra-Oxford’s COVID-19 vaccine candidate, the sentiment around Astra’s share price should improve finally. Besides taking on board the 100% probability of ..."
Pages
69
Language
English
Published on
30/12/20
You may also be interested by these reports :
09/07/25
After integrating the latest figures, we have refined our profitability expectations for the coming years. Given the robust business model, we ...
01/07/25
Back in late-2023, when Sanofi abandoned its 2025 profitability targets to step up its internal R&D efforts, the management had highlighted 12 ...
26/06/25
Downside for 1H25E consensus – FY25E consensus should be fine – Mid-term potential reiterated
24/06/25
Just like Big Pharmas in aggregate, Sanofi’s (Buy; France) shares have gone nowhere over the last two years. After collapsing by c.19% in a day in ...